SMi Group announces the 11th Annual RNA Therapeutics Conference in London on February 19th - 20th 2020.

The field of RNA therapeutics is rapidly expanding, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

The global antisense and RNA therapeutics market size is expected to expand at a compound annual growth rate (CAGR) of 8.6% between 2019 and 2025, when it is projected to reach $1.81 billion. RNA-based drugs, including short interfering RNAs and antisense oligonucleotides, are particularly promising examples of this newer class of biologics. For over two decades, researchers have been trying to overcome major challenges for utilizing such RNAs in a therapeutic context, including intracellular delivery, stability, and immune response activation. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.

This year, we will maintain our focus on the latest research and developments on delivery system technologies that aim to tackle more difficult targets within the human body. This overarching topic warrants high focus and therefore we will, for the first time in the series, introduce a focus day on Oligonucletide Delivery Systems. Our main conference will focus on current developments in the area of mRNA therapeutics in immunotherapy and vaccination. We will also cover a fair bit of regulation, such as continuing upon patenting novel products, release of new 2020 regulations in the clinical trials arena, as well as ensuring compliance. Finally, a significant section that tackles novel and emerging therapies as well as the latest research findings from academia will also be present in this year’s agenda.

Join us in February 2020, as SMi’s RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing.